+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review



Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review



Journal of Infection and Public Health 8(1): 1-10



After highly active antiretroviral therapy (HAART) became widespread, several studies demonstrated changes in the incidence of defining and non-defining AIDS cancers among HIV/AIDS patients. We conducted a systematic review of observational studies evaluating the incidence of malignancies before and after the introduction of HAART in people with HIV/AIDS. Eligible studies were searched up to December 2012 in the following databases: Pubmed, Embase, Scielo, Cancerlit and Google Scholar. In this study, we determined the cancer risk ratio by comparing the pre- and post-HAART eras. Twenty-one relevant articles were found, involving more than 600,000 people with HIV/AIDS and 10,891 new cases of cancers. The risk for the development of an AIDS-defining cancer decreased after the introduction of HAART: Kaposi's sarcoma (RR=0.30, 95% CI: 0.28-0.33) and non-Hodgkin's lymphoma (RR=0.52, 95% CI: 0.48-0.56), in contrast to invasive cervical cancer (RR=1.46, 95% CI: 1.09-1.94). Among the non-AIDS-defining cancers, the overall risk increased after the introduction of HAART (RR=2.00, 95% CI: 1.79-2.23). The incidence of AIDS-defining cancers decreased and the incidence of non-AIDS-defining cancers increased after the early use of HAART, probably due to better control of viral replication, increased immunity and increased survival provided by new drugs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051654388

Download citation: RISBibTeXText

PMID: 25294086

DOI: 10.1016/j.jiph.2014.08.003


Related references

Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from São Paulo, Brazil. International Journal of Std and Aids 28(12): 1190-1198, 2017

Incidence and risk factors of non AIDS-defining as compared with AIDS-defining infections and cancers in a cohort of HIV-infected patients initiating a protease inhibitor -containing regimen. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 320, 2001

Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Medicine 14(8): 481-490, 2014

Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. Journal of Acquired Immune Deficiency Syndromes 52(2): 203-208, 2009

High incidence and aggressive growth of non-AIDS-defining cancers among AIDS patients in Oslo. Apmis 104(10): 729-733, 1996

Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. Journal of Acquired Immune Deficiency Syndromes 34(1): 84-90, 2003

HIV and Cancer: An Overview of AIDS-Defining and Non-AIDS-Defining Cancers in Patients With HIV. Clinical Journal of Oncology Nursing 23(3): 327-331, 2019

Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. Aids Research and Human Retroviruses 31(5): 514-518, 2015

Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study. Annals of Internal Medicine 169(2): 87-96, 2018

AIDS-defining diseases and HIV-related immunodeficiency in patients developing AIDS during the HAART era What is changing?. International Journal of Antimicrobial Agents 19(Suppl. 1): S9, 2002

Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Current Opinion in Oncology 21(5): 445-454, 2009

Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: a case-control study. Sexually Transmitted Infections 76(2): 145-B-146, 2000

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clinical Infectious Diseases 48(8): 1138-1151, 2009

The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. American Journal of Epidemiology 165(10): 1143-1153, 2007

The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Medicine 7(6): 369-377, 2006